WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL) to C$8.50 from C$8.00 and reiterated their Speculative Buy recommendation on the stock following the close of their recent $80 million bought deal.

Doug Taylor, Canaccord’s analyst, now estimates that the company holds roughly $114 million in pro forma cash. Funds from the recent financing are expected to go towards “organic growth initiatives, including its recent apps.health launch, and for additional M&A and strategic investments.”

Taylor says, “Financing strengthens an already sizable war chest for accretive capital allocation.” He adds that the sizeable $114 million in cash WELL has now will go towards M&A or a list of strategic investments, such as the following.

  1. Medical and/or allied health clinics (WELL Health Clinic Network and WELL Allied)
  2. EMR platforms (WELL EMR)
  3. Digital health companies with an emphasis on patient engagement technologies (WELL Digital Health Apps)
  4. Cybersecurity (Cycura)

Although since the Circle Medical deal that was signed at the beginning of September, there has been no new deals, Taylor says, “we understand
the company currently has on the order of 10 signed letters of intent (LOI) in its M&A pipeline, noting that timing and probability of closing from the LOI stage are variable.”

Taylor then touches on their forecast for WELL’s third-quarter results, which will be announced in November. Taylor says that they expect a small growth in Digital Services revenue over the second quarter. This quarter will include early contributions from the Cycura acquisition.

Taylor expects third-quarter revenue to be $11 million and Adjusted EBITDA to be ($0.4) million. His full 2020 year revenue estimate is $44 million with EBITDA of ($0.8) million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Copper Junior Just Secured $96 Million | Simon Quick – Canadian Copper

This Gold Stock Just Doubled — And It Still Looks Cheap | Q-Gold Resources PEA

Silver May Be the Trade of This Crisis | Michael Oliver

Recommended

Antimony Resources Drills 4.38% Sb Over 7.05 Metres At Bald Hill In Final Hole Of 2025 Program

Kirkland Lake Drills 121 Metres Of 1.01 g/t Gold At Mirado

Related News

K92 Mining: Canaccord Raises Target To $12.50 From $8.75

Yesterday morning Canaccord analyst Tom Gallo upgraded his twelve-month price target on K92 Mining (TSXV:...

Wednesday, October 7, 2020, 12:33:00 PM

Canaccord: Headwinds To Begin To Pressure Snap Inc Stock

On Thursday Snap Inc (NYSE: SNAP) reported its first-quarter financial results. The firm reported revenues...

Tuesday, April 26, 2022, 11:28:00 AM

Organigram: Raymond James Drops Price To $3.00 Ahead Of Earnings

On Friday, Raymond James reiterated Organigram Holdings (TSX: OGI) (NASDAQ: OGI)‘ market perform rating while...

Monday, November 23, 2020, 03:24:28 PM

Cresco Labs: Canaccord Maintains Price Target Following FY2020 Results

Last week, Cresco Labs (CSE: CL) reported their fourth quarter and full-year 2020 financial results....

Monday, March 29, 2021, 11:44:00 AM

Cowen & Co Issues US Cannabis Update, Remains Bullish on Green Thumb, Cresco, Curaleaf

On the first of the month, Cowen and Co sent out an industry update specifically...

Sunday, September 6, 2020, 01:37:00 PM